

Application News



MALDI Mass Spectrometry

Analysis of Modification Site of Chemically Modified Antibody Using MALDImini[™]-1 Compact MALDI Digital Ion Trap Mass Spectrometer

Antibody drug conjugates (ADC), which appeared in the 2000s, are a new class of anti-cancer drugs in which an antibody is bound to a cytotoxic drug. Because they combine the high substrate specificity of the antibody and the effect of a low-molecular drug, ADC are expected to be more effective anti-cancer drugs than the conventional low-molecular drugs. When a different compound is bound artificially to a protein, as in the case of ADC, the binding degree of that compound and its binding site become one of the critical quality properties.

Therefore, as reported in the example in this article, a pseudo ADC was created by artificially binding a low-molecular compound to a standard research antibody, and was then analyzed using a MALDImini-1 compact MALDI digital ion trap (DIT) mass spectrometer.

S. Nakaya

Tryptic Digestion and MS Measurement of Antibody

Tryptic digestion of a standard antibody modified with Mefluorescein-ABNO on the tryptophan residue⁽¹⁾ (Fig. 1, NISTmab, humanized IgG κ monoclonal antibody, RM8671) and an untreated standard antibody (1 μ L each) was performed in respective solutions, and the samples were then desalted with a Ziptip[®] μ C18 tip and deposited on the MALDI target plate. The matrix solution (0.5 μ L) was overlaid on the sample and dried, and an MSⁿ analysis was conducted using the MALDImini-1 compact MALDI-DIT mass spectrometer. DHB (2.5-dihydroxybenzoic acid) was used as the matrix. The modified and unmodified antibodies were measured using the MALDImini-1 (Fig. 2), and their mass spectra were compared. Although almost all ions were common to the two samples, some ions (m/z 2416.9, 2430.7, 2452.7, 2560.9) that were detected only in the modified antibody were discovered (Fig. 3).




Fig. 1 Me-fluorescein-ABNO Modification of Antibody



Fig. 2 Appearance of MALDImini[™]-1 Compact MALDI-DIT MS

From the difference in their masses, three of these ions, m/z 2416.9, 2430.7, and 2452.7, were thought to be related to a monomolecular CH₂ elimination product or H/Na substitution product. Therefore, a further analysis of m/z 2416.9 and m/z 2560.9 was carried out, as these were thought to have originated separately from different molecules.




Fig. 3 Comparison of Mass Spectra of Standard Antibodies (Red: Unmodified Antibody, Blue: Modified Antibody)

Analysis of Modification Site by MSⁿ

First, an MS/MS analysis of m/z 2416.9 was performed, and a fragment ion (m/z 1677.7), which is supposed to be the peptide backbone from which the modifying group dissociated, was detected (Fig. 4). Because this ion showed the same m/z value as the ion detected by MS measurement of the unmodified antibody, MS³ measurement of the above-mentioned ion obtained by MS/MS analysis of the modified antibody, and MS/MS measurement of ion having the same m/z value obtained from the MS spectrum of the unmodified antibody were carried out. When the obtained spectra were compared, the two showed the same fragment patterns. Furthermore, the result of a Mascot MS/MS ion search of these data confirmed that this is a peptide sequence (278FNWYVDGVEVHNAK291) originating from a heavy chain of the antibody.

An analysis of the m/z 2560.9 ion was also carried out in the same manner, and it was found that the modifying group also existed in a peptide sequence (305WSVLTVLHQDWLNGK320) that originated from a heavy chain of the antibody (Fig. 5).

Based on these facts, it was suggested that this chemical modification existed in the tryptophan residues in the abovementioned two peptide sequences.




Fig. 4 MSⁿ (n=2, 3) Spectra and Results of Mascot MS/MS Ion Search

The fact that a single antibody molecule was a complex molecule comprising two heavy chain molecules and two light chain molecules suggested that a maximum of four chemical modifications has occurred this time. This is also consistent with the result (existence of three chemical modifications in one antibody molecule) obtained in another experiment (Application News No. B86).

The results of this analysis demonstrated that the MALDImini-1 compact MALDI-DIT mass spectrometer has high MSⁿ analysis capability in spite of its small size, and has the highest possible performance for obtaining information from modified peptides.




Fig. 6 Amino Acid Sequence of Heavy Chain and Modification Sites (Bold: Amino Acid Sequence of Peptide Confirmed by Mascot MS/MS Ion Search, Red: Modification Site of ME-fluorescent-ABNO)

Reference

Yohei Seki, Takashi Ishiyama, Daisuke Sasaki, Junpei Abe, Youhei Sohma, Kounosuke Oisaki, and Motomu Kanai, Transition Metal-Free Tryptophan-Selective (1) Bioconjugation of Proteins. J. Am. Chem. Soc. 2016, 138 (34), 10798-801.

Acknowledgements

We would like to thank the Laboratory of Synthetic Organic Chemistry (Motomu KANAI Group), Graduate School of Pharmaceutical Sciences, The University of Tokyo for preparing the antibody modified with Me-fluorescein-ABNO.

MALDImini is a trademark of Shimadzu Corporation in Japan and/or other countries. Mascot is a registered trademark of Matrix Science Limited. ZipTip is a registered trademark of Merck KGaA.



For Research Use Only. Not for use in diagnostic procedure.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Shimadzu disclaims any proprietary interest in trademarks and trade names used in this publication other than its own. See http://www.shimadzu.com/about/trademarks/index.html for details.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

First Edition: Jun 2019

www.shimadzu.com/an/

Shimadzu Corporation